2014
DOI: 10.1136/jnnp-2014-307672
|View full text |Cite
|
Sign up to set email alerts
|

Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study

Abstract: ObjectiveTo investigate the role of longitudinal plasma neurofilament heavy chain protein (NfH) levels as an indicator of clinical progression and survival in amyotrophic lateral sclerosis (ALS).MethodsA cross-sectional study involving 136 clinically heterogeneous patients with ALS and 104 healthy and neurological controls was extended to include a prospective analysis of 74 of these ALS cases, with samplings at approximately 3-month intervals in a follow-up period of up to 3 years. We analysed the correlation… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

18
109
3

Year Published

2015
2015
2022
2022

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 100 publications
(135 citation statements)
references
References 35 publications
18
109
3
Order By: Relevance
“…Phosphorylated neurofilament heavy chain appears elevated at stable levels throughout the disease [19][20][21][22][23][24][25][26]. Neurofilament light chain in cerebrospinal fluid (CSF) appears to increase as ALS progresses [19,[27][28][29][30][31].…”
Section: Toward Novel Outcome Measures and Biomarkers In Als Trialsmentioning
confidence: 99%
“…Phosphorylated neurofilament heavy chain appears elevated at stable levels throughout the disease [19][20][21][22][23][24][25][26]. Neurofilament light chain in cerebrospinal fluid (CSF) appears to increase as ALS progresses [19,[27][28][29][30][31].…”
Section: Toward Novel Outcome Measures and Biomarkers In Als Trialsmentioning
confidence: 99%
“…Some examples of these approaches, albeit from targeted analyses, have been performed [38,105,169], and have been discussed throughout this review. These studies require large sample sizes consisting of patients with ALS, neurologic disease controls, and healthy controls, in order to assess how particular biomarkers change over time.…”
Section: Current Status and Future Directionsmentioning
confidence: 99%
“…High levels of pNfH in CSF have been described as a biomarker for sALS [22,23]. Plasma NfH levels and disease progression show a close correlation [36].…”
Section: Morphological Studies Of Wobbler Mouse Dorsal Root Ganglia Smentioning
confidence: 99%